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Abstract
Curative resection is crucial to survival in pancreatic cancer; however, despite optimization and stan-
dardization of surgical procedures, this is not always achieved. This review highlights that the rates of
microscopic margin involvement (R1) vary markedly between studies and, although resection margin
status is believed to be a key prognostic factor, the rates of margin involvement and local tumour
recurrence or overall survival of pancreatic cancer patients are often incongruent. Recent studies indicate
that the discrepancy between margin status and clinical outcome is caused by frequent underreporting
of microscopic margin involvement. Lack of standardization of pathological examination, confusing
nomenclature and controversy regarding the definition of microscopic margin involvement have resulted
in the wide variation of reported R1 rates that precludes meaningful comparison of data and clinico-
pathological correlation.
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Introduction
The prognosis for patients with ductal adenocarcinoma of the
pancreas is poor.1 As the response of this cancer to chemo- and
radiotherapy is limited, surgical resection is currently the only
potentially curative treatment. Only 10–20% of pancreatic cancer
patients can undergo surgical resection, and within this patient
group, resection margin (RM) involvement has been established
as a key prognostic factor.2–6
The rate of microscopic RM involvement (R1) reported in the
literature varies markedly, from below 20% to over 75%.7–17 A
recent meta-analysis highlighted that even in randomized con-
trolled trials, in which a higher than average level of standardi-
zation may be expected, the R1 rate ranged from 0% to 83%,
limiting the scope for meaningful comparison and precluding
conclusions regarding the prognostic significance of RM status.18
Because RM involvement is generally believed to be determined
by the quality of surgery, a low R1 rate is often seen as an indicator
of high-quality surgery. Recent studies, however, have brought the
pathologist as a second player into the field, based on the growing
awareness that standardization and meticulousness of the patho-
logical examination have a significant impact on the accuracy of
the reported RM status.16,19,20 The R1 rate is therefore a perfor-
mance measure not only for the surgeon, but possibly also for the
reporting pathologist.
Recent scrutiny of the pathological examination of pancre-
atoduodenectomy (PD) specimens further revealed a stark lack of
consensus regarding terminology and definitions that are key
to the reporting of the RM status.21,22 With this additional set of
confounding factors, concern is growing that pathological report-
ing may be inconsistent and hence bias prediction of outcome,
skew epidemiological data and hamper progress in our under-
standing of the natural history of pancreatic cancer.
The recent development in the pathological assessment of
RMs in pancreatic cancer and the ensuing implications for patient
management are reviewed and discussed in the context of
advances in pancreatic surgery.
Surgical technique and margin involvement
Surgeons over the years have pushed the boundaries of surgical
resection for the limited group of patients with resectable disease
in an attempt to achieve complete tumour clearance with negative
margins.
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The traditional Kausch–Whipple procedure (PD) evolved in
the early 1990s to the pylorus-preserving Kausch–Whipple variant
[pylorus-preserving pancreatoduodenectomy (PPPD)] with ini-
tially varied outcomes reported using the two techniques in large
case series.23–25 A recent Cochrane Database Systematic Review26
and three prospective randomized trials compared the two
techniques27–29 and concluded that there were no long-term sur-
vival differences between the two groups. It is difficult to draw
meaningful conclusions regarding the RM status after PD and
PPPD, as these data are not available for all studies. However, a
detailed account of the RM status was presented in a Dutch study,
which did not observe a significant difference in R1 rate (PD: 17%,
PPPD: 26%, P = 0.23), or indeed in long-term patient survival.29
Interestingly, an international workshop on surgical procedures in
pancreatic cancer recommended that the pylorus-preserving
operation should not be used for carcinomas located in the
antero-superior part of the pancreatic head.30
The same workshop defined the extent of dissection that should
be performed as part of a standard (PP-)PD and a procedure with
extended lymphadenectomy. Although the latter was proposed to
achieve a radical curative resection for pancreatic cancer by care-
ful removal of retroperitoneal lymph nodes and soft tissues, the
Johns Hopkins group found no significant difference in resection
margin status between standard and radical PD (12% vs. 7%; P =
0.11).31 Unfortunately, very limited data are available on margin
status after radical surgery, and in particular no information has
been published on the margins of the extended resection areas.
As randomized trials31–33 failed to show any survival advantage
after extended lymphadenectomy, current recommendation is
for only a standard lymphadenectomy in conjunction with a PD
or PPPD.34
Pancreatic cancers involving the portal vein and/or superior
mesenteric vein can be resected safely either by a lateral sleeve
resection or a segmental resection with or without the use of an
interposition graft. Recent analysis of a large series convincingly
showed that survival of patients after vascular resection is similar
to that of patients in whom vascular resection is not required.35
Less clear, however, is the impact of vascular resection on margin
involvement. While some studies report a higher incidence of RM
involvement after vascular resection,17 others observe no differ-
ence in R1 rate between PD with or without vascular resection.35
These conflicting observations are difficult to reconcile, but com-
parison of the R1 rate for pancreatic resection without vascular
resection in these studies suggests that – as outlined below –
differences in the pathological assessment of the RMs may have
clouded the picture.
Histopathological assessment and margin
involvement
Recent studies from European and UK centres have highlighted
the impact of histopathological examination on the R1 rate.16,19
After introduction of a rigorous standardized pathology protocol,
both groups observed a significant increase in the R1 rate for
pancreatic cancer, from 53% to 85%16 and 14% to 76%.19 A
follow-up study by the UK group confirmed the consistency of
this high R1 rate and thus the robustness of margin assessment
if a detailed standardized protocol is consequently used.20 The
observations of these studies indicate that resection margin
involvement is a common finding in pancreatic cancer, which
risks being under-recognized if pathological examination is not
thorough.
The histopathological diagnostic process encompasses multiple
steps, including specimen dissection, tissue sampling, microscopic
examination, and reporting of findings. As discussed below, each
step is fraught with a lack of consensus and standardization, and
therefore open to different approaches and interpretations that
potentially result in inconsistent reporting of the margin status.
Opinions even differ on what exactly constitutes the resection
margin in PD specimens, and hence, which parts of the specimen
should be included in the pathological examination.
Circumferential resection margins in PD specimens
While evaluation of the transection margins of the pancreatic
neck, common bile duct, stomach and/or duodenum is a well-
established part of routine practice, much confusion exists regard-
ing the circumferential resection margin (CRM), which is in part
a result of differences in terminology.
As illustrated in Fig. 1, it seems sensible to distinguish between
the anterior and posterior surfaces of the pancreatic head, which
are separated by the medial CRM. The latter faces the superior
mesenteric vein (SMV) and has a shallow groove-like shape and
a fairly smooth surface. Flanking the medial (or SMV) CRM to
the left is a relatively small area of rougher texture that faces the
superior mesenteric artery (SMA) and joins by an acute angle the
slightly fibrous but smooth posterior surface of the pancreatic
head, which overlies the aortocaval groove. The posterior CRM is
often referred to as the retroperitoneal margin – a misnomer as
the entire pancreas is located in the retroperitoneum – and some-
times includes the SMA margin.16,17,36 The medial, groove and
SMV margins are used more or less synonymously, whereas the
uncinate process margin and the vascular margin usually refer to
the SMA margin.17,22,37
Controversy exists over the anterior surface of PD specimens as
to whether it should be regarded as part of the CRM. While it is an
anatomical surface, not a true RM, presence of tumour cells at the
anterior surface is likely to increase the risk of local recurrence.
This surface is therefore included in the assessment of the CRM in
some European centres16,19,38 and an integral part of the Japan
Pancreas Society (JPS) classification,39 but usually left uncon-
sidered by pathologists in the USA according to the AJCC re-
commendations.40 Limitation of the assessment to the SMA or
‘uncinate’ margin may at least partially explain the lower R1 rates
observed in some high-volume US pancreatic cancer centres.17
Although microscopic margin involvement is staged as ‘R1’
irrespective of which parts of the CRM are involved, detailed CRM
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mapping is important, first and foremost to allow for feedback to
the surgical team. In addition, through accurate correlation with
multimodality imaging, CRM mapping could facilitate improved
pre-operative assessment of resectability and identification of
areas at risk of incomplete resection. Finally, data from margin
mapping are required to reveal the significance of involvement of
each individual CRM in terms of survival.
Dissection of PD specimens
Existing literature on the pathological examination of PD speci-
mens – national guidelines, standard textbooks and published
single or multicentre studies38,41–45 – reveals that a wide range of
dissection techniques are currently used, many of which follow
tradition rather than evidence-based rationale. While significant
progress has been made through refinement and standardization
of technical procedures in surgery and pre-operative imaging of
pancreatic cancer, histopathology has failed to follow suit.
A recent overview and comparison of the different dissection
techniques21 highlights the advantages of the so-called axial slicing
technique, which has been used increasingly in European and UK
pancreatic cancer centres. As illustrated in Fig. 2, the technique is
based solely on serial slicing of the pancreatic head in an axial
plane, i.e. perpendicular to the longitudinal axis of the duodenum.
It does not prescribe longitudinal opening of the pancreatic or bile
duct, hence the entire surface (or CRM) of the pancreatic head
remains intact. Axial slicing is easy to perform, independent of
the location and nature of the pathology encountered, and allows
extensive views of the lesion and its relationship to key anatomical
structures. Interestingly, axial slicing was the standardized dissec-
tion technique used in the recent studies that reported an unusu-
ally high R1 rate of over 75%.16,19,20 The frequent identification of
margin involvement reported in these studies is at least partially
explained by the fact that all parts of the CRM can be inspected
in each specimen slice obtained with this technique.
Although beyond the scope of this review, it is worth mention-
ing that by using the axial slicing technique, a high lymph node
yield19,20 well above the currently recommended minimum of
15 lymph nodes46,47 can be achieved. Furthermore, if axial slicing
is performed in combination with photodocumentation of the
specimen slices, macroscopic findings can be reviewed in great
detail at any time. This is helpful for the reporting pathologist,
during multidisciplinary case discussion, and, not less impor-
tantly, for pathology review in multicentre trial work. As identifi-
cation of the cancer origin – pancreatic, ampullary or distal bile
duct – is based mainly on gross findings, photographs of specimen
slices would allow pathology review to extend beyond the mere
microscopic re-assessment of the exact tumour type.
Tissue sampling
Unlike other digestive tract cancers in which the invasive tumour
front is usually well-defined and reliably identifiable by gross
inspection, the boundaries of pancreatic and distal bile duct
cancers are often obscured by fibrosis and inflammatory changes
associated with tumour-induced obstructive pancreatitis. The
highly dispersed, discontinuous growth that is characteristic of
pancreatobiliary cancer further contributes to the difficulty of
identifying the tumour periphery. With naked-eye inspection
being unreliable in this respect, extensive sampling of the tumour
and nearest CRMs is essential. Failure to do so will inevitably lead
to underestimation of margin involvement, as the R1 rate corre-
Figure 1 The circumferential resection margin in pancre-
atoduodenectomy (PD) specimens consists of the anterior surface,
the medial surface facing the superior mesenteric vein (SMV),
the surface flanking the superior mesenteric artery (SMA) and the
posterior surface
Figure 2 Slicing of pancreatoduodenectomy (PD) specimens in an
axial plane provides good views of the tumour and its relationship to
the key anatomical structures and the entire circumferential resec-
tion margin
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lates directly with the extent of tissue sampling.16 The importance
of extensive sampling is further supported by a recent molecular
study based on K-ras analysis, which detected cancer cells in the
margins of 53% of PD specimens deemed to be margin-negative
by histological assessment.48
Intra-operative frozen section examination
In many centres, intra-operative frozen section examination is
regularly used to assess possible tumour involvement of the
transection margin of the pancreatic neck or common bile duct.
In contrast, samples from the CRMs are usually not submitted for
intra-operative frozen section. The surgical technique for a stan-
dard PD resection involves clearance of all tissues along the portal
vein/SMV and along the right of the SMA, and therefore these
margins cannot be improved by the surgeon, even if they were
found to be involved using tumour on frozen section analysis.
Recently, protocols for the intra-operative frozen section exami-
nation of the SMA or ‘uncinate’ margin have been proposed37,49
with the intention to guide the surgeon in the extent of resection
around the SMA. However, during a standard PD, any attempt
to resect tissue close to or on the uncinate margin would be by
definition an incomplete resection and runs the risk of a discon-
tinuous resection and creating a positive margin should the
tumour involve the uncinate process. By following the standard
technique for PD the need for intra-operative frozen section
analysis of this margin should be obviated.
Definition of R1: 1 mm clearance?
One further important reason for the remarkable variety in
reported R1 rates is the lack of consensus regarding the definition
of microscopic margin involvement. In the USA, pathologists will
report a margin as positive only if tumour cells are present at the
surface, i.e. if the clearance equals 0 mm.17,45,49 In contrast, many
pathologists in Europe and the UK use a definition based on a
1 mm clearance.38 The latter ‘1 mm rule’ is a mere adoption of the
definition of R1 in rectal cancer, which is based on meticulous
correlation between measured minimum clearance and local
tumour recurrence.50,51 Such a clinicopathological correlational
study has not been performed for pancreatic cancer, mainly
because, for the want of management implications, detailed diag-
nostics are usually not performed in patients presenting with signs
of tumour recurrence.
In the absence of data linking local recurrence rate to minimum
tumour clearance, resort has to be taken to a different approach.
The distance of minimum clearance is obviously determined by
the growth pattern of a particular cancer. Absence of tumour cells
at or within 1 mm to the specimen surface is less likely to indicate
complete resection, i.e. absence of tumour beyond the line of
resection, if the tumour growth pattern is dispersed rather than
compact. A recent study analysing the growth patterns of rectal
cancer and ductal adenocarcinoma of the pancreas revealed a
significantly more dispersed growth pattern of the latter, in par-
ticular in the periphery of the tumour, close to the invasive front.52
Hence, an R1 definition based on a 1 mm clearance that is
adequate for compact-growing rectal cancer, is likely to underes-
timate microscopic margin involvement in pancreatic cancer.
The above considerations apply to the assessment of tumour
involvement of true margins, either transection margins or CRMs.
As the anterior surface of the pancreatic head is an anatomical
surface rather than a surgical margin, it seems sensible to apply the
0 mm clearance rule for the assessment of the anterior surface.
Mode of tumour propagation at the margin –
does it matter?
A further point of controversy regarding microscopic margin
assessment pertains to the mode of tumour propagation: should
tumour cells inside lymphovascular channels, perineural clefts
or lymph nodes within 1 mm to the RM also be reported as R1?
The difficulty in answering this question is twofold. First,
tumour cells within lymphovascular channels and perineural
clefts are in transit and have a mode of spread that differs from
that of cancer cells infiltrating tissue planes. Hence, the above
considerations regarding growth pattern and minimum clear-
ance do not apply.
The second difficulty is of a conceptual nature. Lymphovascular
or perineural tumour propagation indicates a risk of regional
tumour spread. Curative resection is commonly understood as
successful local clearance of a tumour, acknowledging that locore-
gional tumour recurrence as a result of lymph node metastasis
or spread along peripheral nerves cannot be prevented by an R0
resection.
While the confusion regarding margin involvement and
lymphovascular or perineural tumour propagation seems to be
primarily one of concepts and terminology, the question of posi-
tive lymph nodes close to the RM can be addressed by consid-
erations based on tumour growth pattern. Tumour cells inside a
lymph node tend to grow within the confines of the well-defined
lymph node capsule, and hence the 0-mm clearance approach
seems to be appropriate. Ultimately, however, tumour cells
may breach the lymph node capsule and infiltrate the surround-
ing soft tissue, at which stage the R1 definition based on tumour
growth pattern (currently, by default, 1 mm clearance) becomes
applicable.
R1 rate and clinical outcome
Although resection margin involvement is an established prog-
nostic factor, the overall survival figures in series with low R1 rates
do not differ significantly from those with higher R1 rates. Inter-
estingly, as illustrated in Table 1, the best outcome after curative
resection is observed in two studies with the by far highest R1
rate.16,20 In contrast, none of the other listed studies show a cor-
relation between R1 rate and median survival or survival benefit
of curative resection. As expected, the survival figures for non-
curative resections are similar in all studies, indicating a compa-
rable level of care along the patient pathway.
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Both studies with a high R1 rate for pancreatic cancer differ
from the other studies by the fact that pathological examination
was performed according to a rigorous, fully standardized
examination protocol, including axial specimen slicing,
photodocumentation and extensive tissue sampling. Although
both studies are based on small series, and hence confirmation
on larger case numbers is required, their results seem to indicate
that meticulous pathological assessment allows accurate identi-
fication of RM involvement, and consequently, reliable prog-
nostic stratification. In contrast, if pathological assessment
underestimates RM involvement, incorrect reporting of R0
resection obfuscates the difference in outcome between the R0
and R1 subgroups.
The rate of local tumour recurrence is an alternative outcome
measure with which the R1 rate can be compared. Studies based
on imaging or post-mortem findings typically report a local recur-
rence rate for pancreatic cancer of 75–85%.53–55 This seems to be at
odds with the R1 rate, which in the majority of published series
lies well below 30–40%. Interestingly, the local recurrence rate is
significantly lower in ampullary cancer (approximately 28%) than
in distal bile duct cancer (58–74%),56–59 and in some studies this
corresponds with differences in R1 rate for those cancers.16,20,36
Hence, incorrect diagnosis of the tumour origin may lead to inclu-
sion of ampullary or distal bile duct adenocarcinomas in pancre-
atic cancer series and result in a misleadingly low R1 rate.
Despite the current lack of consensus in terminology to denote
the different CRMs, most studies seem to agree that the posterior
and medial CRMs are affected most frequently.16,19,20,59,60 However,
the prognostic significance of tumour involvement of each indi-
vidual CRM is currently not known. While data on detailed CRM
mapping are too scarce to allow any conclusions, occasional
single-centre studies suggest prognostic relevance of particular
CRMs in pancreatic61,62 and distal bile duct cancer.63
The way forward
As histopathology remains the cornerstone for stratification
of pancreatic cancer patients who underwent surgical resec-
tion, consensus regarding the definition of microscopic margin
involvement and standardization of the examination protocol are
important first steps towards improved patient management.
Although standardization is essential to increase consistency
and completeness of histopathology reporting, it does not ensure
diagnostic accuracy. The latter can be achieved only by continu-
ous quality assessment of pancreatic pathology reporting and
comparison against benchmarks that need to be developed once
standardization has been widely implemented and allowed
generation of consistent data. Once standardization and quality
monitoring of pathology are in place, trials to assess novel treat-
ment strategies can be rolled out to multiple national and inter-
national centres without the risk of being biased by inconsistent
pathological data.
Through careful correlation with imaging, accurate pathologi-
cal assessment of the margins could be used to refine pre-
operative prediction of margin involvement, as it is done for rectal
cancer, and assess the impact of pre-operative treatment on resec-
tion margin status.
Novel surgical techniques such as the ‘No touch isolation tech-
nique’ have been developed to reduce cancer cell dissemination by
avoidance of intra-operative tumour manipulation. While the
results in terms of tumour recurrence have yet to be proven, this
technique would have little bearing on resection margins, in par-
ticular if the principles of a standard (PP-)PD are adhered to.64
Conclusions
The currently recommended surgical treatment for pancreatic
cancer is a PD, classic or pylorus-preserving, with a standard
Table 1 Survival data following curative and non-curative surgical resection for pancreatic cancer
Reference (First author/
year)
No of patients RM status R1 rate (%) Median survival
R1/R2 (months)
Median survival
R0 R0 (months)
Menon (2009)20 27 R1 82 14 >55
Westgaard (2008)36 40 R1 45 11 16
Raut (2007)17 360 R1 17 22 28
Verbeke (2006)16 26 R1 85 11 37
Neoptolemos (2001)5 541 R1 19 11 17
Benassai (2000)13 75 R1, R2 20 9 17
Sohn (2000)14 616 R1 30 12 19
Millikan (1999)12 84 R1 29 8 17
Nishimura (1997)11 157 R1, R2 45 6 12
Sperti (1996)10 113 R1, R2 17 7 14
Nitecki (1995)9 174 R2 16 9 NA
Yeo (1995)8 201 R1, R2 29 10 18
Willett (1993)7 72 R1 51 12 20
R0: clear margins; R1: microscopic margin involvement, R2: gross margin involvement.
286 HPB
HPB 2009, 11, 282–289 © 2009 International Hepato-Pancreato-Biliary Association
lymphadenectomy and, in case of vascular involvement,
mesenterico-portal vein resection.
While it is acknowledged that these surgical procedures do not
always result in curative resection, published data on the incidence
of margin involvement vary widely between studies and do not
convincingly correlate with patient outcome.
Recent studies indicate that if pathological assessment is
detailed and standardized, margin involvement is found in >75%
of PD specimens for pancreatic cancer. These observations are not
without important clinical implication. If indeed the majority of
surgical resections are non-curative, then adjuvant treatment
needs to be offered to a much larger patient group.
The reasons for underestimation of margin involvement are
manifold and include, amongst others, controversy regarding the
definition of microscopic margin involvement and the lack of a
detailed, standardized pathology examination protocol. Not only
the management of individual patients, but also the success of
multicentre trials to assess novel treatment strategies will to a large
extent depend on the resolution of these issues. Without robust
and reliable pathological data, trials are unlikely to produce com-
pelling evidence.
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